Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pee power: simple urine test could revolutionize heart failure care

NCT ID NCT07631780

Disease control Sponsor: Nurgul Ablakimova Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether measuring sodium in urine can help doctors give the right amount of diuretics (water pills) to people hospitalized with worsening heart failure. About 260 adults will be split into two groups: one gets standard care, the other gets treatment guided by urine sodium levels and ultrasound scans. The goal is to see if this approach clears fluid buildup faster, reduces the need for stronger treatments, and helps patients go home sooner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Confirmed diagnosis of worsening heart failure (WHF), characterized by symptoms and signs of acute decompensation requiring hospitalization for intensification of intravenous diuretic therapy. * Previous intake of a loop diuretic (torasemide or furosemide) in any dose for at least 2 days before hospitalization. * Presence of clinical signs and symptoms of congestion (e.g., dyspnea, orthopnea, peripheral edema, pulmonary congestion). * Provision of written informed consent. Exclusion Criteria: * Acute coronary syndrome within the previous 30 days. * Acute heart failure requiring urgent invasive intervention, including cardiogenic shock or mechanical circulatory support. * Current admission to an intensive care unit. * Systolic blood pressure ≤90 mmHg or requirement for inotropic/vasopressor support. * Recent use (≤48 hours) of inotropic agents affecting fluid and electrolyte balance. * Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² or requirement for renal replacement therapy. * Hypokalemia (\<3.5 mmol/L) or hyperkalemia (≥5.5 mmol/L). * Clinically significant hyponatremia (\<130 mmol/L) or hypernatremia (\>150 mmol/L). * Significant comorbidities affecting sodium-water balance (e.g., liver cirrhosis with ascites, nephrotic syndrome, severe infection or sepsis). * Pregnancy or breastfeeding. * Active malignancy. * Inability to comply with the study protocol or participation in another interventional clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congestion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

advanced heart failure Edema heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congestion Heart failure Worsening heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • West Kazakhstan Marat Ospanov Medical University

    Aktobe, 030000, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.